Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2009 1
2010 2
2011 1
2012 1
2014 2
2015 4
2016 5
2017 6
2018 6
2019 4
2020 5
2021 3
2022 4
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Congenital Hypothyroidism: Screening and Management.
Rose SR, Wassner AJ, Wintergerst KA, Yayah-Jones NH, Hopkin RJ, Chuang J, Smith JR, Abell K, LaFranchi SH; SECTION ON ENDOCRINOLOGY EXECUTIVE COMMITTEE; COUNCIL ON GENETICS EXECUTIVE COMMITTEE. Rose SR, et al. Among authors: wintergerst ka. Pediatrics. 2023 Jan 1;151(1):e2022060419. doi: 10.1542/peds.2022-060419. Pediatrics. 2023. PMID: 36827523
Congenital Hypothyroidism: Screening and Management.
Rose SR, Wassner AJ, Wintergerst KA, Yayah-Jones NH, Hopkin RJ, Chuang J, Smith JR, Abell K, LaFranchi SH; SECTION ON ENDOCRINOLOGY EXECUTIVE COMMITTEE; COUNCIL ON GENETICS EXECUTIVE COMMITTEE. Rose SR, et al. Among authors: wintergerst ka. Pediatrics. 2023 Jan 1;151(1):e2022060420. doi: 10.1542/peds.2022-060420. Pediatrics. 2023. PMID: 36827521
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
Nrf2 transcriptional upregulation of IDH2 to tune mitochondrial dynamics and rescue angiogenic function of diabetic EPCs.
Dai X, Wang K, Fan J, Liu H, Fan X, Lin Q, Chen Y, Chen H, Li Y, Liu H, Chen O, Chen J, Li X, Ren D, Li J, Conklin DJ, Wintergerst KA, Li Y, Cai L, Deng Z, Yan X, Tan Y. Dai X, et al. Among authors: wintergerst ka. Redox Biol. 2022 Oct;56:102449. doi: 10.1016/j.redox.2022.102449. Epub 2022 Aug 28. Redox Biol. 2022. PMID: 36063728 Free PMC article.
FGF1ΔHBS delays the progression of diabetic nephropathy in late-stage type 2 diabetes mouse model by alleviating renal inflammation, fibrosis, and apoptosis.
Lin Q, Chen O, Wise JP Jr, Shi H, Wintergerst KA, Cai L, Tan Y. Lin Q, et al. Among authors: wintergerst ka. Biochim Biophys Acta Mol Basis Dis. 2022 Aug 1;1868(8):166414. doi: 10.1016/j.bbadis.2022.166414. Epub 2022 Apr 18. Biochim Biophys Acta Mol Basis Dis. 2022. PMID: 35447340 Free PMC article.
Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study.
Van Name MA, Kanapka LG, DiMeglio LA, Miller KM, Albanese-O'Neill A, Commissariat P, Corathers SD, Harrington KR, Hilliard ME, Anderson BJ, Kelley JC, Laffel LM, MacLeish SA, Nathan BM, Tamborlane WV, Wadwa RP, Willi SM, Williams KM, Wintergerst KA, Woerner S, Wong JC, DeSalvo DJ. Van Name MA, et al. Among authors: wintergerst ka. J Diabetes Sci Technol. 2023 Jul;17(4):976-987. doi: 10.1177/19322968221084667. Epub 2022 Mar 26. J Diabetes Sci Technol. 2023. PMID: 35343269 Free PMC article. Clinical Trial.
46 results